CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells

Journal of Cell Communication and Signaling

article

Li, Zhao-Jun¹  Hou, Ya-Jun³  Hao, Gang-Ping²  Pan, Xiao-Xuan²  Fei, Hong-Rong¹  Wang, Feng-Ze² 

[1] School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences;School of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences;Key Lab of Cerebral Microcirculation in Universities of Shandong, Shandong First Medical University & Shandong Academy of Medical Sciences

关键词: CUDC-907;    Breast cancer;    TRAIL;    Apoptosis;    DR5;    MAPK;   

DOI  :  10.1007/s12079-020-00558-3

学科分类：分子生物学，细胞生物学和基因

来源: Springer

【 摘 要 】

CUDC-907 is a novel dual-acting inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC). In this study, we aimed to explore the anticancer effects of CUDC-907 on human breast cancer cells. Our results showed that CUDC-907 effectively inhibited breast cancer cell proliferation. Flow cytometry analysis revealed that CUDC-907 induced cell cycle arrest and apoptosis in breast cancer cells. The combined treatment of CUDC-907 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resulted in a marked increase in apoptosis and cleavage of caspase-8, −9 and poly (ADP-ribose) polymerase (PARP) in breast cancer cells. CUDC-907 enhanced expressions of death receptor 5 (DR5), reduced the levels of anti-apoptotic molecules XIAP, Bcl-2 and Bcl-xL. Knockdown of DR5 abrogated apoptosis induced by the combination of CUDC-907 and TRAIL in breast cancer cells. CUDC-907 increased the phosphorylation of JNK and p38 MAPK. JNK inhibitor pretreatment attenuated CUDC-907-induced upregulation of DR5. In summary, CUDC-907 shows potent cytotoxicity against breast cancer cells and facilitates TRAIL-mediated apoptosis through DR5 upregulation. The combination of CUDC-907 and TRAIL may be a promising therapeutic approach in the treatment of breast cancer.

【 授权许可】

CC BY